HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pioro, E. P. Articles by Ng, T. C. Search for Related Content PubMed PubMed Citation Articles by Pioro, E. P. Articles by Ng, T. C.

1H-MRS evidence of neurodegeneration and excess glutamate glutamine in ALS medulla

From the Departments of Neurology and Neurosciences (Drs. Pioro and Mitsumoto), Radiology (Drs. Majors and Ng), and Biostatistics and Epidemiology (D.R. Nelson), The Cleveland Clinic Foundation, OH.

Address correspondence and reprint requests to Dr. Erik P. Pioro, Department of Neurology, S90, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: pioroe{at}ccf.org

OBJECTIVE: To determine whether short echo-time (TE) proton magnetic resonance spectroscopic imaging (¹H-MRSI) can detect in vivo differences in signal intensities of specific metabolites in the medulla of patients with ALS compared with healthy individuals and whether these metabolites could be useful surrogate markers of disease.

BACKGROUND: ¹H-MRSI can detect N-acetylaspartate +N-acetylaspartylglutamate (abbreviated NAx), which is localized to neurons, and glutamate (Glu) + glutamine (Gln), abbreviated Glx, which may be important in ALS pathogenesis. The medulla is an ideal region to study ALS because of its high density of nuclei and fiber tracts that frequently undergo degeneration, even when more rostral brain regions show minimal pathology.

METHODS: Ten patients with ALS and seven healthy control subjects underwent short TE ¹H-MRSI on a 1.5 T clinical imaging system. Signal intensities of NAx and Glx were normalized to creatine–phosphocreatine and compared between groups.

RESULTS: Compared with normal subjects, the medulla of patients with ALS had 17% lower NAx (p = 0.03) and 55% higher Glx (p = 0.02) signals. Bulbar symptoms, represented by the ALS Functional Rating Scale, correlated with Glx (r = -0.68, p = 0.03) but not NAx (r = 0.22, p = 0.53).

CONCLUSION: There is in vivo ¹H-MRSI evidence of neuronal degeneration or loss and excess Glu + Gln in the medulla of patients with ALS. Although this cross-sectional study cannot identify which change occurred first, the higher Glx signal in the medulla of patients with more dysarthria and dysphagia is consistent with the hypothesis of Glu excitotoxicity in ALS pathogenesis. Longitudinal ¹H-MRSI studies of the medulla (and other brain regions) in more patients with ALS are required to confirm these findings and to determine whether such metabolite changes will be useful in monitoring disease progression, in clinical diagnosis, and in understanding the pathogenesis of ALS.

This article has been cited by other articles:

				H. Mitsumoto, A. M. Ulug, S. L. Pullman, C. L. Gooch, S. Chan, M. -X. Tang, X. Mao, A. P. Hays, A. G. Floyd, V. Battista, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS Neurology, April 24, 2007; 68(17): 1402 - 1410. [Abstract] [Full Text] [PDF]

				M. Dichgans, J. Herzog, T. Freilinger, M. Wilke, and D. P. Auer 1H-MRS alterations in the cerebellum of patients with familial hemiplegic migraine type 1 Neurology, February 22, 2005; 64(4): 608 - 613. [Abstract] [Full Text] [PDF]

				P. Kaufmann, S. L. Pullman, D. C. Shungu, S. Chan, A. P. Hays, M. L. Del Bene, M. A. Dover, M. Vukic, L. P. Rowland, and H. Mitsumoto Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS) Neurology, May 25, 2004; 62(10): 1753 - 1757. [Abstract] [Full Text] [PDF]

				J. Suhy, R.G. Miller, R. Rule, N. Schuff, J. Licht, V. Dronsky, D. Gelinas, A.A. Maudsley, and M.W. Weiner Early detection and longitudinal changes in amyotrophic lateral sclerosis by 1H MRSI Neurology, March 12, 2002; 58(5): 773 - 779. [Abstract] [Full Text] [PDF]

				M. Nagai, M. Aoki, I. Miyoshi, M. Kato, P. Pasinelli, N. Kasai, R. H. Brown Jr, and Y. Itoyama Rats Expressing Human Cytosolic Copper-Zinc Superoxide Dismutase Transgenes with Amyotrophic Lateral Sclerosis: Associated Mutations Develop Motor Neuron Disease J. Neurosci., December 1, 2001; 21(23): 9246 - 9254. [Abstract] [Full Text] [PDF]

				L. P. Rowland and N. A. Shneider Amyotrophic Lateral Sclerosis N. Engl. J. Med., May 31, 2001; 344(22): 1688 - 1700. [Full Text] [PDF]

				B. C. Bowen and W. G. Bradley Amyotrophic Lateral Sclerosis: The Search for a Spectroscopic Marker of Upper Motoneuron Involvement Arch Neurol, May 1, 2001; 58(5): 714 - 716. [Full Text] [PDF]

				C. Pohl, W. Block, J. Karitzky, F. Traber, S. Schmidt, C. Grothe, R. Lamerichs, H. Schild, and T. Klockgether Proton Magnetic Resonance Spectroscopy of the Motor Cortex in 70 Patients With Amyotrophic Lateral Sclerosis Arch Neurol, May 1, 2001; 58(5): 729 - 735. [Abstract] [Full Text] [PDF]

				M. Mascalchi, M. Cosottini, F. Lolli, F. Salvi, C. Tessa, M. Macucci, M. Tosetti, R. Plasmati, A. Ferlini, C. A. Tassinari, et al. Proton MR Spectroscopy of the Cerebellum and Pons in Patients with Degenerative Ataxia Radiology, May 1, 2002; 223(2): 371 - 378. [Abstract] [Full Text] [PDF]